Evidence map›Paper›PMID 39334185›Full record

ArticleJournal of translational medicine2024

METTL3-mediated m6A modification of SIRT1 mRNA affects the progression of diabetic cataracts through cellular autophagy and senescence.

Su Dong, Jiajia Zhang, Yushan Fu, Gege Tang, Jianfeng Chen, Dawei Sun, Yanhua Qi, Nan Zhou

Abstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. NSUN2-mediated mJournal of diabetes investigation · 2025
    Article
  10. Targeting RNA adenosine editing and modification enzymes for RNA therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. The latest progression of N6-methyladenosine (mFrontiers in endocrinology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Su DongDepartment of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Jiajia ZhangDepartment of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Yushan FuDepartment of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Gege TangDepartment of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Jianfeng ChenLaboratory Animal Center, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Dawei SunDepartment of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China. sundawei@hrbmu.edu.cn.
Yanhua QiDepartment of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China. qyh86605643@126.com.
Nan ZhouDepartment of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China. nzhou_hmu@126.com.ORCID 0000-0002-1433-375X

Funding

China Primary Health Care Foundation [2022]005Natural Science Foundation of Heilongjiang Province LH2023H041
6 · The paper itself

Abstract

backgroundThe increasing incidence of diabetes mellitus has established diabetic cataracts (DC) as a significant worldwide public health issue. The mechanisms underlying DC remain unknown, and effective prevention and treatment strategies are lacking. Accordingly, we aimed to explore the role and mechanism behind N6-methyladenosine (m6A) in DC progression.

methodsMethyltransferase-like 3 (METTL3), p21, Beclin1, LC3, and p62 expression levels were measured in human tissues. This study assessed total m6A levels and common m6A-regulated biomarkers in both in vitro and in vivo DC models. Autophagy flux was detected in vitro through Ad-mCherry-GFP-LC3B and Monodansylcadaverine (MDC) staining. Cellular senescence was assessed utilizing the senescence-associated β-galactosidase (SA-β-Gal) assay. Furthermore, the effect of METTL3 on SIRT1 mRNA modification was demonstrated, and its mechanism was elucidated using RT-qPCR, western blot, RNA stability assays, and RIP analysis.

resultsMETTL3, p21, and p62 expression levels were elevated in lens epithelial cells (LECs) from DC patients, while Beclin1 and LC3 levels were reduced. Silencing METTL3-mediated m6A modifications restored high-glucose-induced autophagy inhibition and prevented premature senescence in LECs. Notably, SIRT1720 and Metformin significantly enhanced autophagosome generation and delayed cellular senescence. The m6A-reading protein YTHDF2 bound to m6A modifications, and YTHDF2 silencing significantly reduced METTL3-mediated SIRT1 inactivation.

conclusionsMETTL3 induces senescence in DC by destabilizing SIRT1 mRNA in an m6A-YTHDF2-dependent manner. The METTL3-YTHDF2-SIRT1 axis is a key target and potential pathogenic mechanism in DC.

Indexed as

AdenosineAutophagyCataractCellular SenescenceDisease ProgressionMethyltransferasesRNA, MessengerSirtuin 1AnimalsDiabetes ComplicationsEpithelial CellsFemaleHumansLens, CrystallineMaleMiceAdenosineMethyltransferasesMETTL3 protein, humanN-methyladenosineRNA, MessengerSIRT1 protein, humanSirtuin 1AutophagyCellular senescenceDiabetic cataractm6AMETTL3SIRT1

Identifiers

PMID39334185
PMCPMC11429169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.